Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$1.87
-0.06 (-3.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $566.2M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.7B
P/E
6.9x
↓EV/EBITDA
4.6x
↓ROE
10.4%
↑Gross Margin
68.2%
↑Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
-2.3%
FCF CAGR
-44.5%
FCF margin
16.2%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.49B · net income $399.3M · FCF $404.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $2.49B | $2.49B | $2.55B |
| Net Income | $399.3M | $399.3M | $387.9M |
| EBITDA | $905.3M | $905.3M | $936.2M |
| EPS | — | — | 0.19 |
| Gross Margin | 68.2% | 68.2% | 67.4% |
| Operating Margin | 25.8% | 25.8% | 26.1% |
| Net Margin | 16.1% | 16.1% | 15.2% |
| Balance Sheet | |||
| Debt/Equity | 0.39 | 0.39 | 0.84 |
| Current Ratio | 0.99 | 0.99 | — |
| Cash Flow | |||
| Free Cash Flow | $404.0M | $404.0M | $728.4M |
| Returns | |||
| ROE | 10.4% | 10.4% | 16.1% |
| Valuation | |||
| P/E | 6.93 | 6.93 | — |
| EV/EBITDA | 4.63 | 4.63 | — |
| P/B | 0.98 | 0.98 | — |
| Growth & Yield | |||
| Revenue Growth | -2.3% | -2.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.19 → n/d
Residual
-35.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.